Home>Clinical research>Clinical trials by disease>Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity

How to use the speech recognition tool?

NCT03746522

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl
Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity.

Type: Interventional



Status of the trial: Completed

Orphan Drug Recognition: NA

Inclusion

  • Opening Date: 2020-02-17
  • Closing Date: 2020-03-21

Criteria

More information

Children: Yes

Adults: Yes

Funder Type: industry

HCP: Principal investigators

HCP: Other investigators

Within ERN-EYE members

Principal investigators



Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe

* indicates required

This ERN is supported by: